STAAR Surgical (STAA) Q2 2026 earnings review
Growth Reverses Upward Post-Destocking, But Sequential Margin Pinch Warrants Watching
STAAR Surgical delivered a clean Q2, officially putting the 2025 China destocking crisis in the rearview mirror. Revenue of $93.5M was effectively flat sequentially but up 111% YoY against heavily depressed comps. The volume recovery successfully reached the bottom line, with Net Income turning positive to $8.1M (from a $16.8M loss a year ago). However, the narrative of expanding operating leverage hit a sequential speed bump: Adjusted EBITDA fell from $24.4M in Q1 to $20.0M in Q2, driven by a spike in G&A expenses tied to the new ERP system. With Warren Foust taking the permanent CEO role, the company is establishing a 'clean base' to guide for YoY growth in H2 2026.
🐂 Bull Case
Despite a weak broader Chinese refractive market, EVO ICL is gaining market share. China sales hit $52.3M, up 10% sequentially, with no signs of excess distributor inventory, proving real in-market adoption of the premium EVO+.
The Americas grew 12% YoY, maintaining >$6M in U.S. sales for the second consecutive quarter. This growth is occurring against a backdrop of double-digit declines in traditional laser vision correction procedures.
🐻 Bear Case
Management touted operating leverage, but G&A jumped sequentially from $17.0M in Q1 to $22.7M in Q2, dragging Adjusted EBITDA down by $4.4M sequentially despite flat revenue.
EMEA sales declined 1% YoY. While the ex-Middle East segment grew 12%, the ongoing conflict represents a persistent drag on the region's overall contribution.
⚖️ Verdict: 🟢
Bullish. The 2025 inventory crisis is definitively over. The decoupling of China ICL growth from the broader laser market validates the structural shift to lens-based correction. If ERP costs normalize, margin expansion will follow.
Key Themes
China Segment Growth and EVO+ Adoption
China remains the dominant engine, generating $52.3M in Q2. The growth is Stable sequentially (+10% vs Q1) and Reversing YoY (up over 100% vs the destocking trough). The adoption of the newly launched EVO+ is driving ASP expansion and a favorable product mix. Crucially, management confirmed that sales decoupling from the broader, weaker Chinese refractive market indicates active market share capture from laser-based procedures.
Americas Growth Against Laser Declines
The Americas segment Accelerating share gains against legacy technology. Sales grew 12% YoY, led by the U.S. eclipsing $6M for the second consecutive quarter. Management explicitly noted the broader U.S. laser refractive market has declined at double-digit rates, highlighting the secular shift toward removable, lens-based solutions.
Contradiction in Operating Leverage Narrative
Management stated: 'with a largely fixed cost base... margin expansion will naturally follow revenue growth.' Yet the data contradicts this sequentially. Q2 revenue matched Q1 ($93.5M), but G&A expenses spiked to $22.7M (24.3% of sales) from $17.0M (18.2% of sales) in Q1. This caused Operating Income and Adjusted EBITDA to decelerate sequentially. The culprit: high amortization and outside services for the new Oracle ERP system.
Tariff Drag on Gross Margins
Gross margin stabilized at 74.5% (up from 74.0% YoY and 73.6% in 26Q1), but remains pressured by tariffs on U.S.-manufactured lenses sold to China. Management confirmed this headwind will persist until 100% of China-bound product is manufactured at the Nidau, Switzerland facility, which is targeted for completion by the end of 2026.
Macro Pressures in EMEA
EMEA sales Decelerated, falling 1% YoY. Management isolated the weakness to the Middle East. Excluding the Middle East, the rest of EMEA grew a healthy 12%. Until geopolitical stability returns, this segment will mathematically drag down global ex-China growth metrics.
Transitioning from Product to Platform
Newly permanent CEO Warren Foust is steering STAAR beyond a single-product (Collamer ICL) focus toward a broader refractive platform. A search for a new Chief Technology Officer is underway to accelerate the R&D pipeline. The company also hinted at integrating AI into its new ERP capabilities to improve operational and commercial efficiencies.
Other KPIs
Reversing. A massive improvement from the $27.2 million cash burn in the prior year quarter. Working capital dynamics stabilized, supported by $8.1M in net income and heavy non-cash add-backs (stock-based comp, depreciation). Six-month OCF is still slightly negative (-$2.0M), but the Q2 trajectory is highly positive.
Stable. Up from $163.9 million in Q1, driven by the positive operating cash generation. The balance sheet remains pristine with zero outstanding debt, providing ample runway for DTC marketing investments in Japan and scaling the Swiss facility.
While exact Q2 segment dollars weren't isolated in the PR text, management highlighted Japan as leading the broader APAC ex-China region (which grew 7% YoY). Heavy direct-to-consumer (DTC) investments initiated in late 2025 are generating a clear return on investment, prompting STAAR to funnel incremental funding there for the rest of the year.
Guidance
Accelerating/Stable. Management declined numeric guidance but explicitly set the baseline. Q3 2025 reported $94.7M, but that included a one-time $25.9M deferred 2024 order. Management instructed investors to measure Q3 2026 against the 'adjusted base of $68.8 million', against which they expect 'strong year-over-year growth'.
Stable. Management notes Q4 is a seasonally softer period, but they are planning for year-over-year growth against the 'clean' Q4 2025 baseline of $57.8 million.
Key Questions
ERP Amortization Horizon
G&A expenses spiked sequentially largely due to ERP amortization and ongoing initiatives. What is the expected quarterly run-rate for these ERP-related expenses, and when will they taper off to allow true operating leverage to flow through?
Swiss Plant Transition Economics
You plan to have 100% of China shipments fulfilled by the Nidau facility by the end of 2026 to avoid tariffs. What is the specific basis-point tailwind to gross margin once this transition is fully complete?
Platform Pipeline Expectations
With the search for a new CTO and the stated goal of evolving into a 'platform', what are the closest near-term milestones we should expect for next-generation products or adjacent refractive technologies?
EVO+ Margin Profile
EVO+ is driving favorable ASPs in China. Does EVO+ carry a materially different manufacturing cost profile than legacy EVO, and how does the mix shift impact the long-term 75% gross margin target?